Edward T Ryan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11494065/publications.pdf

Version: 2024-02-01

245 papers	13,644 citations	28190 55 h-index	31759 101 g-index
266 all docs	266 docs citations	266 times ranked	17126 citing authors

#	Article	IF	Citations
1	Disease characteristics and serological responses in patients with differing severity of COVID-19 infection: A longitudinal cohort study in Dhaka, Bangladesh. PLoS Neglected Tropical Diseases, 2022, 16, e0010102.	1.3	18
2	OUP accepted manuscript. Journal of the Pediatric Infectious Diseases Society, 2022, , .	0.6	0
3	Seroprevalence of SARS-CoV-2 antibodies in Bangladesh related to novel coronavirus infection. IJID Regions, 2022, 2, 198-203.	0.5	12
4	Virus-like Particle Display of Vibrio cholerae O-Specific Polysaccharide as a Potential Vaccine against Cholera. ACS Infectious Diseases, 2022, 8, 574-583.	1.8	12
5	Evaluation of Candida auris acquisition in US international travellers using a culture-based screening protocol. Journal of Travel Medicine, 2022, 29, .	1.4	1
6	Mucosal-Associated Invariant T (MAIT) cells are highly activated in duodenal tissue of humans with Vibrio cholerae O1 infection: A preliminary report. PLoS Neglected Tropical Diseases, 2022, 16, e0010411.	1.3	5
7	Repertoires of SARS-CoV-2 epitopes targeted by antibodies vary according to severity of COVID-19. Virulence, 2022, 13, 890-902.	1.8	8
8	Estimating typhoid incidence from community-based serosurveys: a multicohort study. Lancet Microbe, The, 2022, 3, e578-e587.	3.4	22
9	Predicting Vibrio cholerae Infection and Disease Severity Using Metagenomics in a Prospective Cohort Study. Journal of Infectious Diseases, 2021, 223, 342-351.	1.9	25
10	Phylogenetic analysis of SARS-CoV-2 in Boston highlights the impact of superspreading events. Science, 2021, 371, .	6.0	226
11	The effect of transport temperature and time on the recovery of antimicrobial-resistant Enterobacterales in stool. Diagnostic Microbiology and Infectious Disease, 2021, 99, 115210.	0.8	4
12	Reply. Journal of Pediatrics, 2021, 228, 320-323.	0.9	0
13	Reply. Journal of Pediatrics, 2021, 228, 317-319.	0.9	0
14	Yellow Fever Vaccine Administration at Global TravEpiNet (GTEN) Clinics during a Period of Limited Vaccine Availability in the United States, 2017â€“2018. American Journal of Tropical Medicine and Hygiene, 2021, , .	0.6	1
15	Coronavirus Disease 2019 (COVID-19) Diagnostic Clinical Decision Support: A Pre-Post Implementation Study of CORAL (COvid Risk cALculator). Clinical Infectious Diseases, 2021, 73, 2248-2256.	2.9	8
16	Humoral signatures of protective and pathological SARS-CoV-2 infection in children. Nature Medicine, 2021, 27, 454-462.	15.2	137
17	Vibrio cholerae Sialidase-Specific Immune Responses Are Associated with Protection against Cholera. MSphere, 2021, 6, .	1.3	11
18	An assessment of potential biomarkers of environment enteropathy and its association with age and microbial infections among children in Bangladesh. PLoS ONE, 2021, 16, e0250446.	1.1	7

#	Article	IF	Citations
19	Impact of Immunoglobulin Isotype and Epitope on the Functional Properties of Vibrio cholerae O-Specific Polysaccharide-Specific Monoclonal Antibodies. MBio, 2021, 12, .	1.8	8
20	Development of a qualitative real-time RT-PCR assay for the detection of SARS-CoV-2: a guide and case study in setting up an emergency-use, laboratory-developed molecular microbiological assay. Journal of Clinical Pathology, 2021, 74, 496-503.	1.0	5
21	Parenteral Vaccination with a Cholera Conjugate Vaccine Boosts Vibriocidal and Anti-OSP Responses in Mice Previously Immunized with an Oral Cholera Vaccine. American Journal of Tropical Medicine and Hygiene, 2021, 104, 2024-2030.	0.6	5
22	Gut Microbiota and Development of Vibrio cholerae-Specific Long-Term Memory B Cells in Adults after Whole-Cell Killed Oral Cholera Vaccine. Infection and Immunity, 2021, 89, e0021721.	1.0	15
23	A Combination of Metagenomic and Cultivation Approaches Reveals Hypermutator Phenotypes within Vibrio cholerae-Infected Patients. MSystems, 2021, 6, e0088921.	1.7	8
24	Defining Polysaccharide-Specific Antibody Targets against Vibrio cholerae O139 in Humans following O139 Cholera and following Vaccination with a Commercial Bivalent Oral Cholera Vaccine, and Evaluation of Conjugate Vaccines Targeting O139. MSphere, 2021, 6, e0011421.	1.3	3
25	An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates. Cell Host and Microbe, 2021, 29, 1437-1453.e8.	5.1	53
26	Scalable production and immunogenicity of a cholera conjugate vaccine. Vaccine, 2021, 39, 6936-6946.	1.7	7
27	Systemic, Mucosal, and Memory Immune Responses following Cholera. Tropical Medicine and Infectious Disease, 2021, 6, 192.	0.9	4
28	Case 34-2021: A 38-Year-Old Man with Altered Mental Status and New Onset of Seizures. New England Journal of Medicine, 2021, 385, 1894-1902.	13.9	1
29	180. Alterations to the Gut Microbiomes and Acquisition of Bacteria Resistance Elements among US International Travelers. Open Forum Infectious Diseases, 2021, 8, S110-S110.	0.4	0
30	738. Comparison of Characteristics of US International Travelers Seeking Pretravel Health Consultations at US Global TravEpiNet Sites Before and During the COVID-19 Pandemic. Open Forum Infectious Diseases, 2021, 8, S467-S467.	0.4	0
31	Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain. Science, 2021, , eabl6251.	6.0	12
32	Clinical Practices for Measles-Mumps-Rubella Vaccination Among US Pediatric International Travelers. JAMA Pediatrics, 2020, 174, e194515.	3.3	6
33	Prescribing Patterns of Antibiotics for the Self-Treatment of Travelersâ€™ Diarrhea in Global TravEpiNet, 2009â€“2018. Open Forum Infectious Diseases, 2020, 7, ofaa376.	0.4	9
34	Antibody responses after COVID-19 infection in patients who are mildly symptomatic or asymptomatic in Bangladesh. International Journal of Infectious Diseases, 2020, 101, 220-225.	1.5	55
35	Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Science Immunology, 2020, 5, .	5.6	561
36	Distinct Early Serological Signatures Track with SARS-CoV-2 Survival. Immunity, 2020, 53, 524-532.e4.	6.6	334

#	Article	IF	Citations
37	SARS-CoV-2 viral load is associated with increased disease severity and mortality. Nature Communications, 2020, 11, 5493.	5.8	702
38	Evolution of Early SARS-CoV-2 and Cross-Coronavirus Immunity. MSphere, 2020, 5, .	1.3	38
39	Ultrasensitive high-resolution profiling of early seroconversion in patients with COVID-19. Nature Biomedical Engineering, 2020, 4, 1180-1187.	11.6	110
40	Clinical sensitivity and interpretation of PCR and serological COVIDâ€19 diagnostics for patients presenting to the hospital. FASEB Journal, 2020, 34, 13877-13884.	0.2	117
41	Ultra-Sensitive Serial Profiling of SARS-CoV-2 Antigens and Antibodies in Plasma to Understand Disease Progression in COVID-19 Patients with Severe Disease. Clinical Chemistry, 2020, 66, 1562-1572.	1.5	134
42	Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune Responses. Journal of Pediatrics, 2020, 227, 45-52.e5.	0.9	288
43	Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality. Cell, 2020, 183, 1508-1519.e12.	13.5	263
44	Evaluation of a Rapid Point-of-Care Multiplex Immunochromatographic Assay for the Diagnosis of Enteric Fever. MSphere, 2020, 5, .	1.3	11
45	Impact of DNA Extraction Method on Variation in Human and Built Environment Microbial Community and Functional Profiles Assessed by Shotgun Metagenomics Sequencing. Frontiers in Microbiology, 2020, 11, 953.	1.5	40
46	Acquisition of Antibiotic-Resistant Bacteria by U.S. International Travelers. New England Journal of Medicine, 2020, 382, 1372-1374.	13.9	20
47	Preclinical Development of a Fusion Peptide Conjugate as an HIV Vaccine Immunogen. Scientific Reports, 2020, 10, 3032.	1.6	36
48	Acquisition and Long-term Carriage of Multidrug-Resistant Organisms in US International Travelers. Open Forum Infectious Diseases, 2020, 7, ofaa543.	0.4	21
49	Humans Surviving Cholera Develop Antibodies against Vibrio cholerae O-Specific Polysaccharide That Inhibit Pathogen Motility. MBio, 2020, 11, .	1.8	20
50	Transcutaneous Vaccination with Conjugate Typhoid Vaccine Vi-DT Induces Systemic, Mucosal, and Memory Anti-Polysaccharide Responses. American Journal of Tropical Medicine and Hygiene, 2020, 103, 1032-1038.	0.6	1
51	Plasma Immunoglobulin A Responses Against 2SalmonellaTyphi Antigens Identify Patients With Typhoid Fever. Clinical Infectious Diseases, 2019, 68, 949-955.	2.9	28
52	Isolation, Purification, Characterization and Direct Conjugation of the Lipidâ€…Aâ€Free Lipopolysaccharide of Vibrio cholerae O139. Chemistry - A European Journal, 2019, 25, 12946-12956.	1.7	9
53	Induction of systemic, mucosal and memory antibody responses targeting Vibrio cholerae O1 O-specific polysaccharide (OSP) in adults following oral vaccination with an oral killed whole cell cholera vaccine in Bangladesh. PLoS Neglected Tropical Diseases, 2019, 13, e0007634.	1.3	11
54	Case 2-2019: A 36-Year-Old Man with Rash, Abdominal Pain, and Lymphadenopathy. New England Journal of Medicine, 2019, 380, 275-283.	13.9	2

#	Article	IF	Citations
55	Oral immunization with a probiotic cholera vaccine induces broad protective immunity against Vibrio cholerae colonization and disease in mice. PLoS Neglected Tropical Diseases, 2019, 13, e0007417.	1.3	23
56	Characteristics and preparation of the last-minute traveler: analysis of vaccine usage in the Global TravEpiNet Consortium. Journal of Travel Medicine, 2019, 26, .	1.4	16
57	Evaluation of a Screening Method for the Detection of Colistin-Resistant Enterobacteriaceae in Stool. Open Forum Infectious Diseases, 2019, 6, ofz211.	0.4	8
58	Vibriocidal Titer and Protection From Cholera in Children. Open Forum Infectious Diseases, 2019, 6, ofz057.	0.4	17
59	Synthesis of glycocluster-containing conjugates for a vaccine against cholera. Organic and Biomolecular Chemistry, 2019, 17, 4049-4060.	1.5	9
60	Estimating cholera incidence with cross-sectional serology. Science Translational Medicine, 2019, 11, .	5.8	50
61	Bivalent oral cholera vaccination induces a memory B cell response to the V. cholerae O1-polysaccharide antigen in Haitian adults. PLoS Neglected Tropical Diseases, 2019, 13, e0007057.	1.3	8
62	2769. The Clinical and Economic Impact of MMR Vaccinations to Prevent Measles Importations from US Pediatric Travelers Returning from Abroad. Open Forum Infectious Diseases, 2019, 6, S976-S977.	0.4	0
63	Posttranslational Regulation of IL-23 Production Distinguishes the Innate Immune Responses to Live Toxigenic versus Heat-Inactivated Vibrio cholerae. MSphere, 2019, 4, .	1.3	10
64	Immune responses to O-specific polysaccharide (OSP) in North American adults infected with Vibrio cholerae O1 Inaba. PLoS Neglected Tropical Diseases, 2019, 13, e0007874.	1.3	13
65	Typhoid conjugate vaccines: a new tool in the fight against antimicrobial resistance. Lancet Infectious Diseases, The, 2019, 19, e26-e30.	4.6	67
66	Cognate T and B cell interaction and association of follicular helper T cells with B cell responses in Vibrio cholerae O1 infected Bangladeshi adults. Microbes and Infection, 2019, 21, 176-183.	1.0	9
67	The Clinical Impact and Cost-effectiveness of Measles-Mumps-Rubella Vaccination to Prevent Measles Importations Among International Travelers From the United States. Clinical Infectious Diseases, 2019, 69, 306-315.	2.9	9
68	Gone or forgotten? The rise and fall of Zika virus. Lancet Public Health, The, 2018, 3, e109-e110.	4.7	23
69	HIV Infection, Pulmonary Tuberculosis, and COPD in Rural Uganda: A Cross-Sectional Study. Lung, 2018, 196, 49-57.	1.4	27
70	High Rates of Enteric Fever Diagnosis and Lower Burden of Culture-Confirmed Disease in Peri-urban and Rural Nepal. Journal of Infectious Diseases, 2018, 218, S214-S221.	1.9	44
71	Assessing antigen specific HLA-DR+ antibody secreting cell (DR+ASC) responses in whole blood in enteric infections using an ELISPOT technique. Microbes and Infection, 2018, 20, 122-129.	1.0	0
72	Analysis of the Human Mucosal Response to Cholera Reveals Sustained Activation of Innate Immune Signaling Pathways. Infection and Immunity, 2018, 86, .	1.0	21

#	Article	IF	Citations
73	1105. Vibriocidal Titer Variation and Likelihood of Protection in Children Compared With Adults in a Cholera Endemic Area. Open Forum Infectious Diseases, 2018, 5, S331-S331.	0.4	0
74	Cholera: recent updates. Current Opinion in Infectious Diseases, 2018, 31, 455-461.	1.3	26
75	Potentially Serious Drug Interactions Resulting From the Pretravel Health Encounter. Open Forum Infectious Diseases, 2018, 5, ofy266.	0.4	4
76	Morbidity and mortality due to shigella and enterotoxigenic Escherichia coli diarrhoea: the Global Burden of Disease Study 1990â€“2016. Lancet Infectious Diseases, The, 2018, 18, 1229-1240.	4.6	427
77	Extensively Drug-Resistant Typhoid â€" Are Conjugate Vaccines Arriving Just in Time?. New England Journal of Medicine, 2018, 379, 1493-1495.	13.9	72
78	Enabling clinicians to easily find location-based travel health recommendationsâ€"is innovation needed?. Journal of Travel Medicine, 2018, 25, .	1.4	1
79	Human Gut Microbiota Predicts Susceptibility to Vibrio cholerae Infection. Journal of Infectious Diseases, 2018, 218, 645-653.	1.9	60
80	Plasma and memory B cell responses targeting O-specific polysaccharide (OSP) are associated with protection against Vibrio cholerae O1 infection among household contacts of cholera patients in Bangladesh. PLoS Neglected Tropical Diseases, 2018, 12, e0006399.	1.3	38
81	Defining endemic cholera at three levels of spatiotemporal resolution within Bangladesh. Nature Genetics, 2018, 50, 951-955.	9.4	37
82	Anti-O-specific polysaccharide (OSP) immune responses following vaccination with oral cholera vaccine CVD 103-HgR correlate with protection against cholera after infection with wild-type Vibrio cholerae O1 El Tor Inaba in North American volunteers. PLoS Neglected Tropical Diseases, 2018, 12, e0006376.	1.3	28
83	Dried Blood Spots for Measuring Vibrio cholerae-specific Immune Responses. PLoS Neglected Tropical Diseases, 2018, 12, e0006196.	1.3	19
84	Development of a new dipstick (Cholkit) for rapid detection of Vibrio cholerae O1 in acute watery diarrheal stools. PLoS Neglected Tropical Diseases, 2018, 12, e0006286.	1.3	29
85	Conjugate Vaccines from Bacterial Antigens by Squaric Acid Chemistry: A Closer Look. ChemBioChem, 2017, 18, 799-815.	1.3	28
86	Missed Opportunities for Measles, Mumps, Rubella Vaccination Among Departing U.S. Adult Travelers Receiving Pretravel Health Consultations. Annals of Internal Medicine, 2017, 167, 77.	2.0	23
87	Preparing Pediatric International Travelers for Travelersâ€™ Diarrhea. Pediatric Infectious Disease Journal, 2017, 36, 242-243.	1.1	5
88	Plasma and Mucosal Immunoglobulin M, Immunoglobulin A, and Immunoglobulin G Responses to the Vibrio cholerae O1 Protein Immunome in Adults With Cholera in Bangladesh. Journal of Infectious Diseases, 2017, 216, 125-134.	1.9	20
89	What proportion of international travellers acquire a travel-related illness? A review of the literature. Journal of Travel Medicine, 2017, 24, .	1.4	81
90	Travel Characteristics and Pretravel Health Care Among Pregnant or Breastfeeding U.S. Women Preparing for International Travel. Obstetrics and Gynecology, 2017, 130, 1357-1365.	1.2	14

#	Article	IF	Citations
91	Nanomagnetic System for Rapid Diagnosis of Acute Infection. ACS Nano, 2017, 11, 11425-11432.	7.3	12
92	Characteristics of US Travelers to Zika Virusâ€“Affected Countries in the Americas, March 2015â€“October 2016. Emerging Infectious Diseases, 2017, 23, 324-327.	2.0	8
93	Vibrio cholerae genomic diversity within and between patients. Microbial Genomics, 2017, 3, .	1.0	37
94	Recommendations of the Advisory Committee on Immunization Practices for Use of Cholera Vaccine. Morbidity and Mortality Weekly Report, 2017, 66, 482-485.	9.0	34
95	Comparison of the Performance of the TPTest, Tubex, Typhidot and Widal Immunodiagnostic Assays and Blood Cultures in Detecting Patients with Typhoid Fever in Bangladesh, Including Using a Bayesian Latent Class Modeling Approach. PLoS Neglected Tropical Diseases, 2016, 10, e0004558.	1.3	40
96	Immune Responses to an Oral Cholera Vaccine in Internally Displaced Persons in South Sudan. Scientific Reports, 2016, 6, 35742.	1.6	22
97	Single-Cell Analysis of the Plasmablast Response to Vibrio cholerae Demonstrates Expansion of Cross-Reactive Memory B Cells. MBio, 2016, 7, .	1.8	62
98	O-Specific Polysaccharide-Specific Memory B Cell Responses in Young Children, Older Children, and Adults Infected with Vibrio cholerae O1 Ogawa in Bangladesh. Vaccine Journal, 2016, 23, 427-435.	3.2	25
99	A magneto-DNA nanoparticle system for the rapid and sensitive diagnosis of enteric fever. Scientific Reports, 2016, 6, 32878.	1.6	11
100	Refusal of recommended travel-related vaccines among U.S. international travellers in Global TravEpiNet. Journal of Travel Medicine, 2016, 24, taw075.	1.4	51
101	Personal Actions to Minimize Mosquito-Borne Illnesses, Including Zika Virus. Annals of Internal Medicine, 2016, 165, 589.	2.0	7
102	Troubling news from Asia about treating enteric fever: a coming storm. Lancet Infectious Diseases, The, 2016, 16, 508-509.	4.6	8
103	Chemoproteomic profiling of host and pathogen enzymes active in cholera. Nature Chemical Biology, 2016, 12, 268-274.	3.9	53
104	Pre-Travel Medical Preparation of Business and Occupational Travelers. Journal of Occupational and Environmental Medicine, 2016, 58, 76-82.	0.9	24
105	Development of a Simple, Peripheral-Blood-Based Lateral-Flow Dipstick Assay for Accurate Detection of Patients with Enteric Fever. Vaccine Journal, 2016, 23, 403-409.	3.2	9
106	Enumeration of Gut-Homing Î²7-Positive, Pathogen-Specific Antibody-Secreting Cells in Whole Blood from Enterotoxigenic Escherichia coli- and Vibrio cholerae-Infected Patients, Determined Using an Enzyme-Linked Immunosorbent Spot Assay Technique. Vaccine Journal, 2016, 23, 27-36.	3.2	10
107	Antibody Secreting Cell Responses following Vaccination with Bivalent Oral Cholera Vaccine among Haitian Adults. PLoS Neglected Tropical Diseases, 2016, 10, e0004753.	1.3	10
108	Biomarkers of Environmental Enteropathy are Positively Associated with Immune Responses to an Oral Cholera Vaccine in Bangladeshi Children. PLoS Neglected Tropical Diseases, 2016, 10, e0005039.	1.3	25

#	Article	IF	Citations
109	The increased severity in patients presenting to hospital with diarrhea in Dhaka, Bangladesh since the emergence of the hybrid strain of Vibrio cholerae O1 is not unique to cholera patients. International Journal of Infectious Diseases, 2015, 40, 9-14.	1.5	4
110	Fluorescence Polarization Based Nucleic Acid Testing for Rapid and Costâ€Effective Diagnosis of Infectious Disease. Chemistry - A European Journal, 2015, 21, 16359-16363.	1.7	16
111	A Cholera Conjugate Vaccine Containing O-specific Polysaccharide (OSP) of V. cholerae O1 Inaba and Recombinant Fragment of Tetanus Toxin Heavy Chain (OSP:rTTHc) Induces Serum, Memory and Lamina Proprial Responses against OSP and Is Protective in Mice. PLoS Neglected Tropical Diseases, 2015, 9, e0003881.	1.3	59
112	Factors Associated with Non-typhoidal Salmonella Bacteremia versus Typhoidal Salmonella Bacteremia in Patients Presenting for Care in an Urban Diarrheal Disease Hospital in Bangladesh. PLoS Neglected Tropical Diseases, 2015, 9, e0004066.	1.3	25
113	Gut Microbial Succession Follows Acute Secretory Diarrhea in Humans. MBio, 2015, 6, e00381-15.	1.8	150
114	Cholera in pregnancy: Clinical and immunological aspects. International Journal of Infectious Diseases, 2015, 39, 20-24.	1.5	6
115	Comparative Proteomic Analysis Reveals Activation of Mucosal Innate Immune Signaling Pathways during Cholera. Infection and Immunity, 2015, 83, 1089-1103.	1.0	55
116	Typhoid Fever in Young Children in Bangladesh: Clinical Findings, Antibiotic Susceptibility Pattern and Immune Responses. PLoS Neglected Tropical Diseases, 2015, 9, e0003619.	1.3	24
117	Concurrent Pneumonia in Children Under 5 Years of Age Presenting to a Diarrheal Hospital in Dhaka, Bangladesh. American Journal of Tropical Medicine and Hygiene, 2015, 93, 831-835.	0.6	16
118	Diagnostics for invasive Salmonella infections: Current challenges and future directions. Vaccine, 2015, 33, C8-C15.	1.7	107
119	Immunogenicity of the Bivalent Oral Cholera Vaccine Shanchol in Haitian Adults With HIV Infection. Journal of Infectious Diseases, 2015, 212, 779-783.	1.9	17
120	Plasma Leptin Levels in Children Hospitalized with Cholera in Bangladesh. American Journal of Tropical Medicine and Hygiene, 2015, 93, 244-249.	0.6	3
121	Immunocompromised Travelers: Demographic Characteristics, Travel Destinations, and Pretravel Health Care from the U.S. Global TravEpiNet Consortium. American Journal of Tropical Medicine and Hygiene, 2015, 93, 1110-1116.	0.6	33
122	Evaluation of Matrix-Assisted Laser Desorption Ionizationâ€“Time of Flight Mass Spectrometry for Identification of Vibrio cholerae. Journal of Clinical Microbiology, 2015, 53, 329-331.	1.8	7
123	Enteric Fever and Other Causes of Fever and Abdominal Symptoms. , 2015, , 1270-1282.e3.		6
124	Vibrio cholerae Serogroup O139: Isolation from Cholera Patients and Asymptomatic Household Family Members in Bangladesh between 2013 and 2014. PLoS Neglected Tropical Diseases, 2015, 9, e0004183.	1.3	38
125	Vibrio cholerae. , 2015, , 2471-2479.e2.		0
126	Economics of Malaria Prevention in US Travelers to West Africa. Clinical Infectious Diseases, 2014, 58, 11-21.	2.9	9

#	Article	IF	Citations
127	Household Transmission of Vibrio cholerae in Bangladesh. PLoS Neglected Tropical Diseases, 2014, 8, e3314.	1.3	45
128	Antigen-Specific Memory B-cell Responses to Enterotoxigenic Escherichia coli Infection in Bangladeshi Adults. PLoS Neglected Tropical Diseases, 2014, 8, e2822.	1.3	25
129	Circulating Mucosal Associated Invariant T Cells Are Activated in Vibrio cholerae O1 Infection and Associated with Lipopolysaccharide Antibody Responses. PLoS Neglected Tropical Diseases, 2014, 8, e3076.	1.3	78
130	Evaluation in Mice of a Conjugate Vaccine for Cholera Made from Vibrio cholerae O1 (Ogawa) O-Specific Polysaccharide. PLoS Neglected Tropical Diseases, 2014, 8, e2683.	1.3	34
131	Immunogenicity of a Killed Bivalent (O1 and O139) Whole Cell Oral Cholera Vaccine, Shanchol, in Haiti. PLoS Neglected Tropical Diseases, 2014, 8, e2828.	1.3	45
132	Pre-Exposure Rabies Vaccination among US International Travelers: Findings from the Global TravEpiNet Consortium. Vector-Borne and Zoonotic Diseases, 2014, 14, 160-167.	0.6	19
133	Environmental Enteric Dysfunction: Pathogenesis, Diagnosis, and Clinical Consequences. Clinical Infectious Diseases, 2014, 59, S207-S212.	2.9	224
134	Use of Japanese Encephalitis Vaccine in US Travel Medicine Practices in Global TravEpiNet. American Journal of Tropical Medicine and Hygiene, 2014, 91, 694-698.	0.6	24
135	Bacterial Shedding in Household Contacts of Cholera Patients in Dhaka, Bangladesh. American Journal of Tropical Medicine and Hygiene, 2014, 91, 738-742.	0.6	41
136	Salmonella chronic carriage: epidemiology, diagnosis, and gallbladder persistence. Trends in Microbiology, 2014, 22, 648-655.	3.5	227
137	Impact of Ramadan on Clinical and Microbiologic Parameters of Patients Seen at a Diarrheal Hospital in Urban Dhaka, Bangladesh, 1996â€“2012. American Journal of Tropical Medicine and Hygiene, 2014, 90, 294-298.	0.6	4
138	Immune Responses to O-Specific Polysaccharide and Lipopolysaccharide of Vibrio cholerae O1 Ogawa in Adult Bangladeshi Recipients of an Oral Killed Cholera Vaccine and Comparison to Responses in Patients with Cholera. American Journal of Tropical Medicine and Hygiene, 2014, 90, 873-881.	0.6	30
139	Cellular and Cytokine Responses to Salmonella enterica Serotype Typhi Proteins in Patients with Typhoid Fever in Bangladesh. American Journal of Tropical Medicine and Hygiene, 2014, 90, 1024-1030.	0.6	26
140	Pre-Travel Preparation of US Travelers Going Abroad to Provide Humanitarian Service, Global TravEpiNet 2009â€“2011. American Journal of Tropical Medicine and Hygiene, 2014, 90, 553-559.	0.6	13
141	Immunoproteomic Analysis of Antibody in Lymphocyte Supernatant in Patients with Typhoid Fever in Bangladesh. Vaccine Journal, 2014, 21, 280-285.	3.2	36
142	Immune Responses to the O-Specific Polysaccharide Antigen in Children Who Received a Killed Oral Cholera Vaccine Compared to Responses following Natural Cholera Infection in Bangladesh. Vaccine Journal, 2013, 20, 780-788.	3.2	35
143	Antibody-Secreting Cell Responses after Vibrio cholerae O1 Infection and Oral Cholera Vaccination in Adults in Bangladesh. Vaccine Journal, 2013, 20, 1592-1598.	3.2	31
144	Natural Selection in a Bangladeshi Population from the Cholera-Endemic Ganges River Delta. Science Translational Medicine, 2013, 5, 192ra86.	5.8	77

#	Article	IF	Citations
145	Non-Typhoidal Salmonella Gastroenteritis at a Diarrheal Hospital in Dhaka, Bangladesh, 1996â€“2011. American Journal of Tropical Medicine and Hygiene, 2013, 88, 661-669.	0.6	21
146	Travel Characteristics and Yellow Fever Vaccine Usage Among US Global TravEpiNet Travelers Visiting Countries with Risk of Yellow Fever Virus Transmission, 2009â€“2011. American Journal of Tropical Medicine and Hygiene, 2013, 88, 954-961.	0.6	13
147	Pre-Travel Health Care of Immigrants Returning Home to Visit Friends and Relatives. American Journal of Tropical Medicine and Hygiene, 2013, 88, 376-380.	0.6	56
148	Evaluation of a Typhoid/Paratyphoid Diagnostic Assay (TPTest) Detecting Anti-Salmonella IgA in Secretions of Peripheral Blood Lymphocytes in Patients in Dhaka, Bangladesh. PLoS Neglected Tropical Diseases, 2013, 7, e2316.	1.3	48
149	Evaluation of an Electricity-free, Culture-based Approach for Detecting Typhoidal Salmonella Bacteremia during Enteric Fever in a High Burden, Resource-limited Setting. PLoS Neglected Tropical Diseases, 2013, 7, e2292.	1.3	23
150	Identification of Immunogenic Salmonella enterica Serotype Typhi Antigens Expressed in Chronic Biliary Carriers of S. Typhi in Kathmandu, Nepal. PLoS Neglected Tropical Diseases, 2013, 7, e2335.	1.3	39
151	Study of Avidity of Antigen-Specific Antibody as a Means of Understanding Development of Long-Term Immunological Memory after Vibrio cholerae O1 Infection. Vaccine Journal, 2013, 20, 17-23.	3.2	29
152	Antibody Avidity in Humoral Immune Responses in Bangladeshi Children and Adults following Administration of an Oral Killed Cholera Vaccine. Vaccine Journal, 2013, 20, 1541-1548.	3.2	14
153	Pre-Travel Health Preparation of Pediatric International Travelers: Analysis From the Global TravEpiNet Consortium. Journal of the Pediatric Infectious Diseases Society, 2013, 2, 327-334.	0.6	30
154	Identification ofIn Vivo-Induced Bacterial Proteins during Human Infection with Salmonella enterica Serotype Paratyphi A. Vaccine Journal, 2013, 20, 712-719.	3.2	21
155	The Intestinal Pathobiome: Its Reality and Consequences Among Infants and Young Children in Resource-Limited Settings. Journal of Infectious Diseases, 2013, 208, 1732-1733.	1.9	23
156	Implications of Acquired Environmental Enteric Dysfunction for Growth and Stunting in Infants and Children Living in Low- and Middle-Income Countries. Food and Nutrition Bulletin, 2013, 34, 357-364.	0.5	146
157	Systemic Antibody Responses to the Immunodominant p23 Antigen and p23 Polymorphisms in Children with Cryptosporidiosis in Bangladesh. American Journal of Tropical Medicine and Hygiene, 2012, 86, 214-222.	0.6	26
158	Factors Associated with Encephalopathy in Patients with Salmonella enterica Serotype Typhi Bacteremia Presenting to a Diarrheal Hospital in Dhaka, Bangladesh. American Journal of Tropical Medicine and Hygiene, 2012, 86, 698-702.	0.6	16
159	Immune responses to cholera in children. Expert Review of Anti-Infective Therapy, 2012, 10, 435-444.	2.0	39
160	Memory B Cell Responses to Vibrio cholerae O1 Lipopolysaccharide Are Associated with Protection against Infection from Household Contacts of Patients with Cholera in Bangladesh. Vaccine Journal, 2012, 19, 842-848.	3.2	75
161	Global TravEpiNet: A National Consortium of Clinics Providing Care to International Travelersâ€”Analysis of Demographic Characteristics, Travel Destinations, and Pretravel Healthcare of High-Risk US International Travelers, 2009â€“2011. Clinical Infectious Diseases, 2012, 54, 455-462.	2.9	115
162	Antigen-Specific Memory T Cell Responses after Vaccination with an Oral Killed Cholera Vaccine in Bangladeshi Children and Comparison to Responses in Patients with Naturally Acquired Cholera. Vaccine Journal, 2012, 19, 1304-1311.	3.2	37

#	Article	IF	Citations
163	Comparison of Immune Responses to the O-Specific Polysaccharide and Lipopolysaccharide of Vibrio cholerae O1 in Bangladeshi Adult Patients with Cholera. Vaccine Journal, 2012, 19, 1712-1721.	3.2	69
164	Memory B Cell and Other Immune Responses in Children Receiving Two Doses of an Oral Killed Cholera Vaccine Compared to Responses following Natural Cholera Infection in Bangladesh. Vaccine Journal, 2012, 19, 690-698.	3.2	44
165	Cholera. Lancet, The, 2012, 379, 2466-2476.	6.3	527
166	Frequency of Reexposure to Vibrio cholerae O1 Evaluated by Subsequent Vibriocidal Titer Rise after an Episode of Severe Cholera in a Highly Endemic Area in Bangladesh. American Journal of Tropical Medicine and Hygiene, 2012, 87, 921-926.	0.6	22
167	Case 38-2011. New England Journal of Medicine, 2011, 365, 2306-2316.	13.9	5
168	Simple, Direct Conjugation of Bacterial O-SPâ€“Core Antigens to Proteins: Development of Cholera Conjugate Vaccines. Bioconjugate Chemistry, 2011, 22, 2179-2185.	1.8	52
169	Case 20-2011. New England Journal of Medicine, 2011, 364, 2536-2541.	13.9	5
170	Cholera in the 21st century. Current Opinion in Infectious Diseases, 2011, 24, 472-477.	1.3	91
171	Genetic Diversity of Cryptosporidium spp. from Bangladeshi Children. Journal of Clinical Microbiology, 2011, 49, 2307-2310.	1.8	27
172	Antigen-Specific Memory B-Cell Responses in Bangladeshi Adults after One- or Two-Dose Oral Killed Cholera Vaccination and Comparison with Responses in Patients with Naturally Acquired Cholera. Vaccine Journal, 2011, 18, 844-850.	3.2	71
173	LPLUNC1 Modulates Innate Immune Responses to Vibrio cholerae. Journal of Infectious Diseases, 2011, 204, 1349-1357.	1.9	45
174	Comparison of Memory B Cell, Antibody-Secreting Cell, and Plasma Antibody Responses in Young Children, Older Children, and Adults with Infection Caused by Vibrio cholerae O1 El Tor Ogawa in Bangladesh. Vaccine Journal, 2011, 18, 1317-1325.	3.2	38
175	Mucosal Immunologic Responses in Cholera Patients in Bangladesh. Vaccine Journal, 2011, 18, 506-512.	3.2	49
176	Vibrio cholerae O1 Infection Induces Proinflammatory CD4+T-Cell Responses in Blood and Intestinal Mucosa of Infected Humans. Vaccine Journal, 2011, 18, 1371-1377.	3.2	33
177	Antibody Responses to the Immunodominant Cryptosporidium gp15 Antigen and gp15 Polymorphisms in a Caseâ€“Control Study of Cryptosporidiosis in Children in Bangladesh. American Journal of Tropical Medicine and Hygiene, 2011, 85, 97-104.	0.6	33
178	The Cholera Pandemic, Still with Us after Half a Century: Time to Rethink. PLoS Neglected Tropical Diseases, 2011, 5, e1003.	1.3	50
179	In Vivo Expression of Salmonella enterica Serotype Typhi Genes in the Blood of Patients with Typhoid Fever in Bangladesh. PLoS Neglected Tropical Diseases, 2011, 5, e1419.	1.3	51
180	Meeting Cholera's Challenge to Haiti and the World: A Joint Statement on Cholera Prevention and Care. PLoS Neglected Tropical Diseases, 2011, 5, e1145.	1.3	105

#	Article	IF	Citations
181	Individuals with Le(a+bâ˚) Blood Group Have Increased Susceptibility to Symptomatic Vibrio cholerae O1 Infection. PLoS Neglected Tropical Diseases, 2011, 5, e1413.	1.3	32
182	Interferon-Î³ and Proliferation Responses to Salmonella enterica Serotype Typhi Proteins in Patients with S. Typhi Bacteremia in Dhaka, Bangladesh. PLoS Neglected Tropical Diseases, 2011, 5, e1193.	1.3	30
183	Preâ€travel Health Adviceâ€Seeking Behavior Among US International Travelers Departing From Boston Logan International Airport. Journal of Travel Medicine, 2010, 17, 387-391.	1.4	102
184	Familial Aggregation of Vibrio cholerae-associated Infection in Matlab, Bangladesh. Journal of Health, Population and Nutrition, 2010, 27, 733-8.	0.7	11
185	Relatedness of Vibrio cholerae O1/O139 Isolates from Patients and Their Household Contacts, Determined by Multilocus Variable-Number Tandem-Repeat Analysis. Journal of Bacteriology, 2010, 192, 4367-4376.	1.0	56
186	Concomitant EnterotoxigenicEscherichia coliInfection Induces Increased Immune Responses toVibrio choleraeO1 Antigens in Patients with Cholera in Bangladesh. Infection and Immunity, 2010, 78, 2117-2124.	1.0	20
187	Development of Immunoglobulin M Memory to Both a T-Cell-Independent and a T-Cell-Dependent Antigen following Infection withVibrio choleraeO1 in Bangladesh. Infection and Immunity, 2010, 78, 253-259.	1.0	23
188	Characterization of Anti- Salmonella enterica Serotype Typhi Antibody Responses in Bacteremic Bangladeshi Patients by an Immunoaffinity Proteomics-Based Technology. Vaccine Journal, 2010, 17, 1188-1195.	3.2	49
189	Informal Urban Settlements and Cholera Risk in Dar es Salaam, Tanzania. PLoS Neglected Tropical Diseases, 2010, 4, e631.	1.3	101
190	Analysis of Salmonella enterica Serotype Paratyphi A Gene Expression in the Blood of Bacteremic Patients in Bangladesh. PLoS Neglected Tropical Diseases, 2010, 4, e908.	1.3	26
191	Severe, Acute Watery Diarrhea in an Adult. PLoS Neglected Tropical Diseases, 2010, 4, e898.	1.3	12
192	Comparison of clinical features and immunological parameters of patients with dehydrating diarrhoea infected with Inaba or Ogawa serotypes of Vibrio cholerae O1. Scandinavian Journal of Infectious Diseases, 2010, 42, 48-56.	1.5	20
193	Immunologic Responses to Vibrio cholerae in Patients Co-Infected with Intestinal Parasites in Bangladesh. PLoS Neglected Tropical Diseases, 2009, 3, e403.	1.3	68
194	Comparative Proteomic Analysis of the PhoP Regulon in Salmonella enterica Serovar Typhi Versus Typhimurium. PLoS ONE, 2009, 4, e6994.	1.1	61
195	Memory T-Cell Responses to Vibrio cholerae O1 Infection. Infection and Immunity, 2009, 77, 5090-5096.	1.0	46
196	Antigen-Specific Memory B-Cell Responses to Vibrio cholerae O1 Infection in Bangladesh. Infection and Immunity, 2009, 77, 3850-3856.	1.0	110
197	Clinical Outcomes in Household Contacts of Patients with Cholera in Bangladesh. Clinical Infectious Diseases, 2009, 49, 1473-1479.	2.9	144
198	Salmonella enterica Serovar Typhi-Specific Immunoglobulin A Antibody Responses in Plasma and Antibody in Lymphocyte Supernatant Specimens in Bangladeshi Patients with Suspected Typhoid Fever. Vaccine Journal, 2009, 16, 1587-1594.	3.2	54

#	Article	IF	Citations
199	Transcutaneous immunization with a synthetic hexasaccharide-protein conjugate induces anti-Vibrio cholerae lipopolysaccharide responses in mice. Vaccine, 2009, 27, 4917-4922.	1.7	23
200	Proteomic Analysis of Vibrio cholerae in Human Stool. Infection and Immunity, 2008, 76, 4145-4151.	1.0	25
201	Application of In Vivo Induced Antigen Technology (IVIAT) to Bacillus anthracis. PLoS ONE, 2008, 3, e1824.	1.1	26
202	Cholera Toxinâ€“Specific Memory B Cell Responses Are Induced in Patients with Dehydrating Diarrhea Caused byVibrio choleraeO1. Journal of Infectious Diseases, 2008, 198, 1055-1061.	1.9	45
203	A Comparison of Clinical and Immunologic Features in Children and Older Patients Hospitalized With Severe Cholera in Bangladesh. Pediatric Infectious Disease Journal, 2008, 27, 986-992.	1.1	43
204	Susceptibility to Vibrio cholerae Infection in a Cohort of Household Contacts of Patients with Cholera in Bangladesh. PLoS Neglected Tropical Diseases, 2008, 2, e221.	1.3	196
205	Shifting Prevalence of Major Diarrheal Pathogens in Patients Seeking Hospital Care during Floods in 1998, 2004, and 2007 in Dhaka, Bangladesh. American Journal of Tropical Medicine and Hygiene, 2008, 79, 708-714.	0.6	101
206	Shifting prevalence of major diarrheal pathogens in patients seeking hospital care during floods in 1998, 2004, and 2007 in Dhaka, Bangladesh. American Journal of Tropical Medicine and Hygiene, 2008, 79, 708-14.	0.6	55
207	Complexity of rice-water stool from patients with Vibrio cholerae plays a role in the transmission of infectious diarrhea. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 19091-19096.	3.3	62
208	Transcutaneous Immunization with Clostridium difficile Toxoid A Induces Systemic and Mucosal Immune Responses and Toxin A-Neutralizing Antibodies in Mice. Infection and Immunity, 2007, 75, 2826-2832.	1.0	53
209	Case 29-2007. New England Journal of Medicine, 2007, 357, 1239-1246.	13.9	4
210	Infectious diseases of severe weather-related and flood-related natural disasters. Current Opinion in Infectious Diseases, 2006, 19, 408-414.	1.3	166
211	Identification of In Vivo-Induced Bacterial Protein Antigens during Human Infection with Salmonella enterica Serovar Typhi. Infection and Immunity, 2006, 74, 5161-5168.	1.0	67
212	Transcutaneous Immunization with Toxin-Coregulated Pilin A Induces Protective Immunity against Vibrio cholerae O1 El Tor Challenge in Mice. Infection and Immunity, 2006, 74, 5834-5839.	1.0	38
213	Postgenomic approaches to cholera vaccine development. Expert Review of Vaccines, 2006, 5, 337-346.	2.0	6
214	Live attenuated oral cholera vaccines. Expert Review of Vaccines, 2006, 5, 483-494.	2.0	55
215	The Practice of Travel Medicine: Guidelines by the Infectious Diseases Society of America. Clinical Infectious Diseases, 2006, 43, 1499-1539.	2.9	234
216	DIARRHEAL EPIDEMICS IN DHAKA, BANGLADESH, DURING THREE CONSECUTIVE FLOODS: 1988, 1998, AND 2004. American Journal of Tropical Medicine and Hygiene, 2006, 74, 1067-1073.	0.6	180

#	Article	IF	Citations
217	PRIMAQUINE: REPORT FROM CDC EXPERT MEETING ON MALARIA CHEMOPROPHYLAXIS I. American Journal of Tropical Medicine and Hygiene, 2006, 75, 402-415.	0.6	283
218	Diarrheal epidemics in Dhaka, Bangladesh, during three consecutive floods: 1988, 1998, and 2004. American Journal of Tropical Medicine and Hygiene, 2006, 74, 1067-73.	0.6	68
219	Prevention of Infection in Adult Travelers After Solid Organ Transplantation. American Journal of Transplantation, 2005, 5, 8-14.	2.6	75
220	Transcriptional Profiling of Vibrio cholerae Recovered Directly from Patient Specimens during Early and Late Stages of Human Infection. Infection and Immunity, 2005, 73, 4488-4493.	1.0	103
221	Reduction in Capsular Content and Enhanced Bacterial Susceptibility to Serum Killing of Vibrio cholerae O139 Associated with the 2002 Cholera Epidemic in Bangladesh. Infection and Immunity, 2005, 73, 6577-6583.	1.0	22
222	Case 19-2005. New England Journal of Medicine, 2005, 352, 2628-2636.	13.9	36
223	Hyperinfectivity of Human-Passaged Vibrio cholerae Can Be Modeled by Growth in the Infant Mouse. Infection and Immunity, 2005, 73, 6674-6679.	1.0	82
224	Case 39-2005. New England Journal of Medicine, 2005, 353, 2697-2705.	13.9	5
225	Blood Group, Immunity, and Risk of Infection with Vibrio cholerae in an Area of Endemicity. Infection and Immunity, 2005, 73, 7422-7427.	1.0	195
226	Incomplete Correlation of Serum Vibriocidal Antibody Titer with Protection fromVibrio choleraeInfection in Urban Bangladesh. Journal of Infectious Diseases, 2004, 189, 2318-2322.	1.9	93
227	In vivo induced antigen technology (IVIAT). Cellular Microbiology, 2004, 7, 1-9.	1.1	66
228	The Major Subunit of the Toxin-Coregulated Pilus TcpA Induces Mucosal and Systemic Immunoglobulin A Immune Responses in Patients with Cholera Caused by Vibrio cholerae O1 and O139. Infection and Immunity, 2004, 72, 4448-4454.	1.0	45
229	Vaccination strategies. Clinics in Occupational and Environmental Medicine, 2004, 4, 27-43.	0.5	1
230	Medical problems in the returning expatriate. Clinics in Occupational and Environmental Medicine, 2004, 4, 205-219.	0.5	9
231	CRYPTOSPORIDIOSIS AMONG BANGLADESHI CHILDREN WITH DIARRHEA: A PROSPECTIVE, MATCHED, CASE-CONTROL STUDY OF CLINICAL FEATURES, EPIDEMIOLOGY AND SYSTEMIC ANTIBODY RESPONSES. American Journal of Tropical Medicine and Hygiene, 2004, 71, 412-419.	0.6	49
232	Cryptosporidiosis among Bangladeshi children with diarrhea: a prospective, matched, case-control study of clinical features, epidemiology and systemic antibody responses. American Journal of Tropical Medicine and Hygiene, 2004, 71, 412-9.	0.6	29
233	Antigen-Specific Immunoglobulin A Antibodies Secreted from Circulating B Cells Are an Effective Marker for Recent Local Immune Responses in Patients with Cholera: Comparison to Antibody-Secreting Cell Responses and Other Immunological Markers. Infection and Immunity, 2003, 71, 4808-4814.	1.0	79
234	Use of invivo-induced antigen technology (IVIAT) to identify genes uniquely expressed during human infection withVibrio cholerae. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 8508-8513.	3.3	129

#	Article	IF	Citations
235	Case 20-2002. New England Journal of Medicine, 2002, 346, 2069-2076.	13.9	33
236	Illness after International Travel. New England Journal of Medicine, 2002, 347, 505-516.	13.9	290
237	Comparison of mucosal and systemic humoral immune responses after transcutaneous and oral immunization strategies. Vaccine, 2002, 20, 2720-2726.	1.7	29
238	Clostridium difficileâ€“Associated Diarrhea. Archives of Internal Medicine, 2001, 161, 525.	4.3	288
239	Cholera Vaccines. Journal of Travel Medicine, 2001, 8, 82-091.	1.4	16
240	Development of a Î” glnA Balanced Lethal Plasmid System for Expression of Heterologous Antigens by Attenuated Vaccine Vector Strains of Vibrio cholerae. Infection and Immunity, 2000, 68, 221-226.	1.0	39
241	Optimizing the Germfree Mouse Model for In Vivo Evaluation of Oral Vibrio cholerae Vaccine and Vector Strains. Infection and Immunity, 2000, 68, 977-981.	1.0	22
242	Health Advice and Immunizations for Travelers. New England Journal of Medicine, 2000, 342, 1716-1725.	13.9	160
243	In Vitro and In Vivo Analyses of Constitutive and In Vivo-Induced Promoters in Attenuated Vaccine and Vector Strains of Vibrio cholerae. Infection and Immunity, 2000, 68, 1171-1175.	1.0	21
244	In Vivo Expression and Immunoadjuvancy of a Mutant of Heat-Labile Enterotoxin ofEscherichia coliin Vaccine and Vector Strains ofVibrio cholerae. Infection and Immunity, 1999, 67, 1694-1701.	1.0	39
245	In Vivo Expression and Immunoadjuvancy of a Mutant of Heat-Labile Enterotoxin of Escherichia coli in Vaccine and Vector Strains of Vibrio cholerae. Infection and Immunity, 1999, 67, 1694-1701.	1.0	7